Showing 4601-4610 of 7638 results for "".
- Renaissance and GlaxoSmithKline Transfer Nine Productshttps://practicaldermatology.com/news/20130605-renaissance_and_glaxosmithkline_transfer_nine_products/2459522/Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's bra…
- Results of SB204 Clinical Study in Acne Releasedhttps://practicaldermatology.com/news/20130605-results_of_sb204_clinical_study_in_acne_released/2459523/Nitric oxide releasing drug candidate SB204 reduces colonization of the acne-causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers, according to a recent trial. This study, in combination with Novan Therapeutics' earlier findings regarding sebum production, suggests …
- Research Shows CLn BodyWash Effective for Children with Eczemahttps://practicaldermatology.com/news/20130603-research_shows_cln_bodywash_effective_for_children_with_eczema/2459524/Clinical study results show that TopMD Skin Care's CLn BodyWash helps ease the symptoms of eczema. The article, “A Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis,” details the results of 18 children ages 2 to 11 with mode…
- Levia Targeted Phototherapy Now Part of Daavlinhttps://practicaldermatology.com/news/20130531-levia_targeted_phototherapy_now_part_of_daavlin/2459525/Daavlin has been appointed by Lerner Medical Devices to exclusively manufacture, sell, and support their Levia Targeted Home Phototherapy Device. The Levia device complements Daavlin's line of home units for the treatment of skin disorders such as psoriasis, vitiligo, and eczema. Product warranties…
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for Colorescience, also formerly of S…
- Valeant Pharmaceuticals to Acquire Bausch + Lombhttps://practicaldermatology.com/news/20130528-valeant_pharmaceuticals_to_acquire_bausch__lomb/2459529/Valeant Pharmaceuticals International, Inc. and Bausch + Lomb Holdings Incorporated entered into a definitive agreement under which Valeant will acquire Bausch + Lomb, a global eye health company, for $8.7 billion in cash. Under terms of the agreement, Valeant will pay aggregate consid…
- FDA Rejects Valeant's Efinaconazole for Onychomycosishttps://practicaldermatology.com/news/20130528-fda_rejects_valeants_efinaconazole_for_onychomycosis/2459530/The FDA rejected Valeant Pharmaceuticals' New Drug Application for efinaconazole for the treatment of onychomycosis. The questions raised by the FDA that precluded the approval pertain only to Chemistry, Manufacturing and Controls areas of the container closure apparatus. As no effica…
- Workshops Added to Aesthetic Extender Symposium 2013https://practicaldermatology.com/news/20130524-workshops_added_to_aesthetic_extender_symposium_2013/2459531/Five additional workshops will be held at the Aesthetic Extender Symposium (AES) at the Boca Raton Resort & Club from October 31 - November 3: Friday, November 1, 3:45 - 5:45 PM Innovations in Facial Aesthetic Medicine: Mastering the Art and Science of Injectables Michael Kane, MD & Jason Pozner,…
- Actavis to Acquire Warner Chilcotthttps://practicaldermatology.com/news/20130521-actavis_to_acquire_warner_chilcott/2459533/Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. If successfully completed, the transaction will create a global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest US specia…
- Clark Pharmaceuticals, Ferndale Healthcare Launch DerMendhttps://practicaldermatology.com/news/20130521-clark_pharmaceuticals_ferndale_healthcare_launch_dermend/2459534/Clark Pharmaceuticals partnered with Ferndale Healthcare to launch DerMend Moisturizing Bruise Formula. The formula is predicated on the idea that skin over 50 tends to get thinner and bruises more easily. Blood thinners, even those like low-dose baby aspirin, can cause skin to bruise. DerMend is d…